аЯрЁБс;ўџ ўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџ§џџџџџџџ ўџџџўџџџўџџџўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџRoot Entryџџџџџџџџџџџџўџџџџџџџџџџџџџџџўџџџџџџџџџџџџџџџўџџџџџџџџџџџџџџџўџџџ Л ЬсАСт\pCalc BАaР= œЏМ=@ 8X@"Зк1мCalibri1ШџArial1ШџArial1ШџArial1мМCalibri1мCalibri ЄGeneral Ѕ#,##0.00рЄѕџ Р рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рѕџ єР рЄ Р р+ѕџ №Р р)ѕџ №Р р,ѕџ №Р р*ѕџ №Р р ѕџ №Р рЄ (Р рЄ(Р рЄ(Р рЅ Р рЄ(8Р рЄ (Р рЄ(Р “€џ“€џ“€џ“€џ“€џ“€џ`…"Nprinceton new jersey 08540…"item 901 financial stateme…j signatures…"„"new immune data from ongoi…$%new immune data from ongoi-1ŒССTыz№r№83 №П Р@@ё  їќ$"Princeton, New Jersey, 08540[  ]IWritten communications pursuant to Rule 425 under the Securities Act.GSoliciting material pursuant to Rule 14a-12 under the Exchange Act.SPre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.UPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.-Item 9.01. Financial Statements and Exhibits.Exhibit Number Description2Press Release of Advaxis, Inc. dated July 15, 2019 SIGNATURESADVAXIS, INC. (Registrant)Date: July 15, 2019By:/s/ Molly HendersonMolly Henderson8Executive Vice President and Chief Financial OfficerxNew Immune Data from Ongoing ADXS-NEO Phase 1 Study Support Clinical Potential for Neoantigen-Directed ImmunotherapiesЯ%lCD8+ T Cell Reactivity Against 90% of Personalized Neoantigen Targets Confirmed in First of Two PatientseProof-of-Mechanism for Off-the-Shelf ADXS-HOT Program with CD8+ T Cells Against Hotspot MutationsAntigen Spreading Confirmed.CD8+ T cells were also generated against the hotspot mutations found within each of the two patients tumors (i.e., EGFRL858R in the NSCLC patient and KRAS G12A in the MSS-CRC patient). This is important for the ADXS-NEO program as Advaxis believes a number of patient tumors likely will present with hotspot mutations, and generating or maintaining CD8+ T cell activity against these targets may increase the potential for killing cancer cells. All of the first four patients in this Phase 1 trial had a hotspot mutation.  This is also relevant for the company s ADXS-HOT program in that this is the first time Advaxis has observed the ability to generate or maintain specific CD8+ T cell activity against hotspot mutations.  Hotspot mutations are important targets contained within the numerous drug constructs within the ADXS-HOT program and the specific hotspot mutations in these two patients, EGFRL858R and KRAS G12A, are included in the company s ADXS-503 (HOT Lung) and ADXS-508 (HOT Colorectal) drug constructs, respectively.>Antigen spreading was confirmed in the MSS-CRC patient showing specific CD8+ T cells against neoepitopes that were not contained in the drug construct prepared for this patient (the NSCLC patient s sample was not re-tested for antigen spreading).  Thus, Advaxis believes ADXS-NEO may be able to induce a specific immune response against neoantigen-bearing tumor cells with the resultant cell death releasing secondary (nontargeted) tumor antigens. These secondary antigens can then prime subsequent immune responses (antigen spread) that are thought to be responsible for the improved clinical outcomes documented with other immunotherapies.  Of note, antigen spreading has also been induced with other Lm constructs such as ADXS-HPV and ADXS-PSA in cervical and prostate cancer patients, respectively.To date, dosing of ADXS-NEO at 1x108 colony forming units (CFU) has been well-tolerated in two patients.  ADXS-NEO dosed at 1x109 CFU was beyond the maximum tolerated dose with reversible Grade 3 hypoxia (n=2) and Grade 3 hypotension (n=1) dose-limiting toxicities.џ  cc Л Ь d-Cыт6?_€%,С*+‚ƒ„&ffffffц?'ffffffц?(ш?)ш?Ё"d,, Ж` Ж`р? Ж` Ж`р?U} З} ЮU} А ,,,, ,§ О§ § § § § § § § х ьP№H№№0№( № №>Ж@<dggџџџџ Л Ь d-Cыт6?_€%,С*+‚ƒ„&ffffffц?'ffffffц?(ш?)ш?Ё"d,, Ж` Ж`р? Ж` Ж`р?U} Л} А} Х2} А,,,§ О§ § ~ лš§  х ьP№H №№0№( № №>Ж@<dggџџџџ Л Ь d-Cыт6?_€%,С*+‚ƒ„&ffffffц?'ffffffц?(ш?)ш?Ё"d,, Ж` Ж`р? Ж` Ж`р?U} О} З} Х8} А ,,@,,,,,§  О§  §  §  О § § § § х"ьP№H0№ №0№( № № >Ж@<dggџџџџ Л Ь d-Cыт6?_€%,С*+‚ƒ„&ffffffц?'ffffffц?(ш?)ш?Ё"d,, Ж` Ж`р? Ж` Ж`р?U} А} З} гd} А,,,,§ О§ § § § § § х ьP№H@№№0№( № №>Ж@<dggџџџџ Л Ь d-Cыт6?_€%,С*+‚ƒ„&ffffffц?'ffffffц?(ш?)ш?Ё"d,, Ж` Ж`р? Ж` Ж`р?U} А} З} гd} А,,,§ § § § § § ьP№HP№№0№( № №>Ж@<dggџџџџ ўџџџўџџџўџџџ ўџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџџўџ џџџџРFMicrosoft Excel 97-TabelleBiff8ўџр…ŸђљOhЋ‘+'Гй0|8 @ L X d pщ§0@@@€еј sСе@€еј sСеўџеЭеœ.“—+,љЎDеЭеœ.“—+,љЎ\щ§ HШарьєќ AppVersion DocSecurityHyperlinksChangedLinksUpToDate ScaleCrop ShareDocщ§12.0000 Root EntryџџџџџџџџРFWorkbookџџџџl'CompObjџџџџџџџџIOle џџџџџџџџџџџџSummaryInformation(џџџџџџџџЌDocumentSummaryInformation8џџџџџџџџџџџџhџџџџџџџџџџџџўџџџџџџџџџџџџџџџўџџџ